[{"id":"5d8be821-57f9-4a69-b151-4d28ee8d8c8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT07472517","created_at":"2026-03-28T01:39:51.238Z","updated_at":"2026-03-28T01:39:51.238Z","phase":"Phase 3","brief_title":"DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy","source_id_and_acronym":"NCT07472517","lead_sponsor":"Boehringer Ingelheim","biomarkers":" DLL3","pipe":" | ","alterations":" DLL3 expression","tags":["DLL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DLL3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • etoposide IV • obrixtamig (BI 764532)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 670","initiation":"Initiation: 04/10/2026","start_date":" 04/10/2026","primary_txt":" Primary completion: 09/10/2028","primary_completion_date":" 09/10/2028","study_txt":" Completion: 04/16/2029","study_completion_date":" 04/16/2029","last_update_posted":"2026-03-16"},{"id":"e8b91e71-29e4-4b49-a8d1-038d6c000854","acronym":"HPN328-4001","url":"https://clinicaltrials.gov/study/NCT04471727","created_at":"2021-01-18T21:29:07.037Z","updated_at":"2025-02-25T12:37:38.530Z","phase":"Phase 1/2","brief_title":"A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)","source_id_and_acronym":"NCT04471727 - HPN328-4001","lead_sponsor":"Harpoon Therapeutics, Inc., a subsidiary of Merck \u0026 Co., Inc. (Rahway, New Jersey USA)","biomarkers":" DLL3","pipe":" | ","alterations":" DLL3 expression","tags":["DLL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DLL3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)"],"overall_status":"Recruiting","enrollment":" Enrollment 232","initiation":"Initiation: 12/14/2020","start_date":" 12/14/2020","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-20"},{"id":"48a9756f-4a13-44e2-87fd-34412cf0be4b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05990738","created_at":"2023-08-14T14:10:29.956Z","updated_at":"2025-02-25T14:09:58.704Z","phase":"Phase 1","brief_title":"DAREONTM-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy","source_id_and_acronym":"NCT05990738","lead_sponsor":"Boehringer Ingelheim","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e topotecan • obrixtamig (BI 764532)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 02/14/2024","start_date":" 02/14/2024","primary_txt":" Primary completion: 01/21/2026","primary_completion_date":" 01/21/2026","study_txt":" Completion: 11/21/2026","study_completion_date":" 11/21/2026","last_update_posted":"2025-02-18"},{"id":"84573df1-6556-4bd1-8122-88ef0fa3cd96","acronym":"","url":"https://clinicaltrials.gov/study/NCT05879978","created_at":"2023-05-30T14:05:15.128Z","updated_at":"2025-02-25T16:33:29.735Z","phase":"Phase 1/2","brief_title":"A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3","source_id_and_acronym":"NCT05879978","lead_sponsor":"Boehringer Ingelheim","biomarkers":" DLL3","pipe":" | ","alterations":" DLL3 expression","tags":["DLL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DLL3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e obrixtamig (BI 764532) • ezabenlimab (BI 754091)"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 07/28/2023","start_date":" 07/28/2023","primary_txt":" Primary completion: 09/05/2025","primary_completion_date":" 09/05/2025","study_txt":" Completion: 09/05/2025","study_completion_date":" 09/05/2025","last_update_posted":"2025-02-07"},{"id":"cd1de8a7-094e-49cc-8165-4980d260787c","acronym":"SKYBRIDGE","url":"https://clinicaltrials.gov/study/NCT05652686","created_at":"2022-12-15T14:58:20.111Z","updated_at":"2025-02-25T16:27:12.251Z","phase":"Phase 1/2","brief_title":"A Study of Peluntamig (PT217) in Patients with Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)","source_id_and_acronym":"NCT05652686 - SKYBRIDGE","lead_sponsor":"Phanes Therapeutics","biomarkers":" EGFR • DLL3","pipe":" | ","alterations":" DLL3 expression","tags":["EGFR • DLL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DLL3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • paclitaxel • etoposide IV • peluntamig (PT217)"],"overall_status":"Recruiting","enrollment":" Enrollment 203","initiation":"Initiation: 09/05/2023","start_date":" 09/05/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-01-31"},{"id":"dbe9ba45-3c65-4db5-a79b-e7b6343a502a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05916313","created_at":"2023-06-23T13:09:23.183Z","updated_at":"2024-07-02T16:35:00.395Z","phase":"Phase 1","brief_title":"A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3","source_id_and_acronym":"NCT05916313","lead_sponsor":"Boehringer Ingelheim","biomarkers":" DLL3","pipe":" | ","alterations":" DLL3 expression","tags":["DLL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DLL3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e obrixtamig (BI 764532)"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":" Primary completion: 08/17/2026","primary_completion_date":" 08/17/2026","study_txt":" Completion: 08/17/2026","study_completion_date":" 08/17/2026","last_update_posted":"2024-05-29"},{"id":"52a22d82-52f6-4985-b6ec-f15e1a181507","acronym":"","url":"https://clinicaltrials.gov/study/NCT04429087","created_at":"2021-01-18T21:19:55.746Z","updated_at":"2024-07-02T16:35:10.281Z","phase":"Phase 1","brief_title":"A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3","source_id_and_acronym":"NCT04429087","lead_sponsor":"Boehringer Ingelheim","biomarkers":" DLL3","pipe":" | ","alterations":" DLL3 expression","tags":["DLL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DLL3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e obrixtamig (BI 764532)"],"overall_status":"Recruiting","enrollment":" Enrollment 282","initiation":"Initiation: 07/15/2020","start_date":" 07/15/2020","primary_txt":" Primary completion: 09/02/2024","primary_completion_date":" 09/02/2024","study_txt":" Completion: 09/22/2025","study_completion_date":" 09/22/2025","last_update_posted":"2024-04-10"},{"id":"a814259a-a8c1-4ee2-ab56-308f9e50f558","acronym":"","url":"https://clinicaltrials.gov/study/NCT05978284","created_at":"2023-08-07T14:08:46.766Z","updated_at":"2024-07-02T16:35:30.517Z","phase":"Phase 1/2","brief_title":"Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma","source_id_and_acronym":"NCT05978284","lead_sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","biomarkers":" DLL3","pipe":"","alterations":" ","tags":["DLL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alveltamig (ZG006)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 10/27/2023","start_date":" 10/27/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-11-03"},{"id":"8339e713-54fb-436e-b405-f5f09796300c","acronym":"QLS31904-101","url":"https://clinicaltrials.gov/study/NCT05461287","created_at":"2022-07-18T14:01:29.153Z","updated_at":"2024-07-02T16:36:00.599Z","phase":"Phase 1","brief_title":"Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05461287 - QLS31904-101","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" DLL3","pipe":" | ","alterations":" DLL3 expression","tags":["DLL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DLL3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e QLS31904"],"overall_status":"Recruiting","enrollment":" Enrollment 290","initiation":"Initiation: 09/30/2022","start_date":" 09/30/2022","primary_txt":" Primary completion: 09/25/2024","primary_completion_date":" 09/25/2024","study_txt":" Completion: 05/25/2025","study_completion_date":" 05/25/2025","last_update_posted":"2022-11-10"}]